At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
Opioid Agonist +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prescription Medications: Pharmacodynamics and Interaction Effects
In Brief
A Phase 1 clinical trial evaluating Opioid Agonist and Sedatives for Opioid Use and Sedative Use. Completed, enrolled 11 participants across 1 site.
Detailed Summary
This study will examine the effects of doses of opioid/placebo and doses of sedative/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use, Sedative Use
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartMar 2019
First PostedMar 2020
Primary CompletionMay 2023
TodayJul 2026
First PostedMar 19, 2020
Enrollment StartMar 25, 2019
Primary CompletionMay 6, 2023
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6.3 years ago
Interventions
Opioid Agonistdrug
Abuse liability evaluation.
Sedativesdrug
Abuse liability evaluation.